| Dana Allen Johnson, MD | |
|
617 23rd St, Suite 19, Ashland, KY 41101-2845 | |
| (606) 325-2221 | |
| (606) 324-1326 |
| Full Name | Dana Allen Johnson |
|---|---|
| Gender | Male |
| Speciality | Hematology/oncology |
| Experience | 38 Years |
| Location | 617 23rd St, Ashland, Kentucky |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1073512133 | NPI | - | NPPES |
| 0829787 | Other | OH | OHIO MEDICAID |
| 64255433 | Medicaid | KY |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RH0002X | Internal Medicine - Hospice And Palliative Medicine | 25543 (Kentucky) | Secondary |
| 207RH0003X | Internal Medicine - Hematology & Oncology | 25543 (Kentucky) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Saint Joseph Mount Sterling | Mount sterling, KY | Hospital |
| Saint Joseph East | Lexington, KY | Hospital |
| Saint Joseph Hospital | Lexington, KY | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Saint Joseph Health System Inc | 4183641400 | 34 |
News Archive
British researchers say a new blood test which is able to detect signs of breast cancer four years earlier than it would be picked up by a standard mammogram, could be available within months.
Freestanding children's hospitals had the largest financial losses for pediatric inpatients covered by Medicaid, suggesting hospitals may be unlikely to offset decreased Disproportionate Share Hospital payments from caring for fewer uninsured patients as a result of health insurance expansion, according to an article published online by JAMA Pediatrics.
Using advanced imaging technology to more precisely target radiation beams to treat soft tissue cancers (sarcomas) in the extremities significantly reduces long term side effects without effecting survival rates, according to research results published online today in the Journal of Clinical Oncology.
Omeros Corporation today announced that it has submitted to the U.S. Food and Drug Administration (FDA) an investigational new drug (IND) application to initiate the Phase 2 clinical program for OMS721, the company's lead human monoclonal antibody targeting mannan-binding lectin‑associated serine protease-2 (MASP-2), the key regulator of the lectin pathway of the immune system.
The number of patients receiving radiation therapy in the United States for cancer treatment is expected to increase by more than 20 percent over the next decade to almost 600,000 per year. But radiation research over the past decade has decreased substantially, making it more difficult to provide oncologists with the best training in the latest techniques, particularly the integration of medical physics, which is now a required aspect in the clinical practice of radiotherapy.
› Verified 3 days ago
| Entity Name | Flaget Healthcare Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1104988203 PECOS PAC ID: 5890692024 Enrollment ID: O20031216000799 |
News Archive
British researchers say a new blood test which is able to detect signs of breast cancer four years earlier than it would be picked up by a standard mammogram, could be available within months.
Freestanding children's hospitals had the largest financial losses for pediatric inpatients covered by Medicaid, suggesting hospitals may be unlikely to offset decreased Disproportionate Share Hospital payments from caring for fewer uninsured patients as a result of health insurance expansion, according to an article published online by JAMA Pediatrics.
Using advanced imaging technology to more precisely target radiation beams to treat soft tissue cancers (sarcomas) in the extremities significantly reduces long term side effects without effecting survival rates, according to research results published online today in the Journal of Clinical Oncology.
Omeros Corporation today announced that it has submitted to the U.S. Food and Drug Administration (FDA) an investigational new drug (IND) application to initiate the Phase 2 clinical program for OMS721, the company's lead human monoclonal antibody targeting mannan-binding lectin‑associated serine protease-2 (MASP-2), the key regulator of the lectin pathway of the immune system.
The number of patients receiving radiation therapy in the United States for cancer treatment is expected to increase by more than 20 percent over the next decade to almost 600,000 per year. But radiation research over the past decade has decreased substantially, making it more difficult to provide oncologists with the best training in the latest techniques, particularly the integration of medical physics, which is now a required aspect in the clinical practice of radiotherapy.
› Verified 3 days ago
| Entity Name | Saint Joseph Health System Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1659624435 PECOS PAC ID: 4183641400 Enrollment ID: O20051026000806 |
News Archive
British researchers say a new blood test which is able to detect signs of breast cancer four years earlier than it would be picked up by a standard mammogram, could be available within months.
Freestanding children's hospitals had the largest financial losses for pediatric inpatients covered by Medicaid, suggesting hospitals may be unlikely to offset decreased Disproportionate Share Hospital payments from caring for fewer uninsured patients as a result of health insurance expansion, according to an article published online by JAMA Pediatrics.
Using advanced imaging technology to more precisely target radiation beams to treat soft tissue cancers (sarcomas) in the extremities significantly reduces long term side effects without effecting survival rates, according to research results published online today in the Journal of Clinical Oncology.
Omeros Corporation today announced that it has submitted to the U.S. Food and Drug Administration (FDA) an investigational new drug (IND) application to initiate the Phase 2 clinical program for OMS721, the company's lead human monoclonal antibody targeting mannan-binding lectin‑associated serine protease-2 (MASP-2), the key regulator of the lectin pathway of the immune system.
The number of patients receiving radiation therapy in the United States for cancer treatment is expected to increase by more than 20 percent over the next decade to almost 600,000 per year. But radiation research over the past decade has decreased substantially, making it more difficult to provide oncologists with the best training in the latest techniques, particularly the integration of medical physics, which is now a required aspect in the clinical practice of radiotherapy.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dana Allen Johnson, MD Po Box 936, London, KY 40743-0936 Ph: (606) 330-7818 | Dana Allen Johnson, MD 617 23rd St, Suite 19, Ashland, KY 41101-2845 Ph: (606) 325-2221 |
News Archive
British researchers say a new blood test which is able to detect signs of breast cancer four years earlier than it would be picked up by a standard mammogram, could be available within months.
Freestanding children's hospitals had the largest financial losses for pediatric inpatients covered by Medicaid, suggesting hospitals may be unlikely to offset decreased Disproportionate Share Hospital payments from caring for fewer uninsured patients as a result of health insurance expansion, according to an article published online by JAMA Pediatrics.
Using advanced imaging technology to more precisely target radiation beams to treat soft tissue cancers (sarcomas) in the extremities significantly reduces long term side effects without effecting survival rates, according to research results published online today in the Journal of Clinical Oncology.
Omeros Corporation today announced that it has submitted to the U.S. Food and Drug Administration (FDA) an investigational new drug (IND) application to initiate the Phase 2 clinical program for OMS721, the company's lead human monoclonal antibody targeting mannan-binding lectin‑associated serine protease-2 (MASP-2), the key regulator of the lectin pathway of the immune system.
The number of patients receiving radiation therapy in the United States for cancer treatment is expected to increase by more than 20 percent over the next decade to almost 600,000 per year. But radiation research over the past decade has decreased substantially, making it more difficult to provide oncologists with the best training in the latest techniques, particularly the integration of medical physics, which is now a required aspect in the clinical practice of radiotherapy.
› Verified 3 days ago
Padma Venkatraman, MD Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 101 Ashland Dr, Ashland, KY 41101 Phone: 606-324-1996 Fax: 606-833-2430 | |
Amr Idris, M.D. Hematology & Oncology Medicare: Medicare Enrolled Practice Location: 613 23rd St Ste 230, Ashland, KY 41101 Phone: 606-324-4745 Fax: 606-324-4941 | |
Paula K Larsen, MD Hematology & Oncology Medicare: Medicare Enrolled Practice Location: 1000 Ashland Dr Ste G1, Ashland, KY 41101 Phone: 606-408-4900 Fax: 606-408-6643 | |
Michael Don Canty, M.D. Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 617 23rd St, Suite 11, Ashland, KY 41101 Phone: 606-324-3188 Fax: 606-329-2237 | |
Dr. Ryann Acquino Pangan, M.D. Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 613 23rd St Ste 130, Ashland, KY 41101 Phone: 606-329-9335 Fax: 606-324-6383 | |
Dr. Francisco Fernandez-gonzalez, Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 613 23rd St Ste 310, Ashland, KY 41101 Phone: 606-833-2161 | |
Dr. Chad Jacob Tarabolous, M.D. Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 617 23rd St, Suite 19, Ashland, KY 41101 Phone: 606-325-2221 Fax: 606-324-1326 |